Figure 1.

Forest plots of characteristics associated with outcomes at 1 year, resulting from multivariable analyses: (a) functional decline; (b) hospitalisation; (c) all-cause mortality. 95%CI: confidence interval at 95%; HR: hazard ratio; severe frailty: Clinical Frailty Scale ≥7; severe polypharmacy: ≥ 10 drugs/day. Functional decline was defined as an absolute loss of Barthel index between two consecutive measures during the 1-year follow-up. Patients were considered overtreated when GLT with a high risk of hypoglycaemia (insulin, sulfonylureas and/or glinides) was taken and HbA_1c was <53 mmol/mol (7.0%) (for patients in good health), < 58 mmol/mol (7.5%) (for patients in intermediate health) or < 64 mmol/mol (8.0%) (for patients in poor health). The above-mentioned health status category was defined according to the criteria of the Endocrine Society Guidelines (2019) [15]. Group intervention: intervention used in the OPERAM trial consisted of a Systematic Tool to Reduce Inappropriate Prescribing (STRIP) described in [19].^*The number of previous hospitalisations was entered as a time-varying variable in the models.